Recent presentations at major lung cancer conferences highlighted multiple therapeutic advances for non-small cell and small cell lung cancer (NSCLC, SCLC). Among key findings, a Phase 2 study showed subcutaneous amivantamab plus lazertinib produced high response rates in EGFR-mutated NSCLC. Additionally, new data from the NADIM ADJUVANT trial demonstrated the benefit of adjuvant chemo-immunotherapy in resected NSCLC. However, mixed outcomes emerged as Summit Therapeutics’ ivonescimab failed to deliver overall survival benefit in a Phase 3 trial. Also, Daiichi Sankyo and Merck’s antibody-drug conjugate showed promising efficacy in extensive-stage SCLC and received breakthrough therapy designation.